Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-2184PMID 17473190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Oncogene].

  2019cited by this paper
• Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.

  2006cited by this paper
• Molecular markers of gliomas: a clinical approach

  2006cited by this paper
• Reclassification of oligoastrocytomas by loss of heterozygosity studies

  2006cited by this paper
• Distinct transcription profiles of primary and secondary glioblastoma subgroups.

  2006cited by this paper
• Different angiogenic phenotypes in primary and secondary glioblastomas

  2006cited by this paper
• CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.

  2005cited by this paper
• Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma

  2005cited by this paper
• Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas

  2005cited by this paper
• Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies.

  2005cited by this paper
• Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Genetic pathways to glioblastomas

  2005cited by this paper
• O6‐methylguanine‐DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course

  2005cited by this paper
• Gliomas: advances in molecular analysis and characterization.

  2005cited by this paper
• Protein patterns and proteins that identify subtypes of glioblastoma multiforme

  2004cited by this paper
• Imaging Correlates of Molecular Signatures in Oligodendrogliomas

  2004cited by this paper
• Correlation of Clinical Features and Methylation Status of MGMT Gene Promoter in Glioblastomas

  2004cited by this paper
• Genetic Pathways to Glioblastoma

  2004cited by this paper
• CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas

  2004cited by this paper
• Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors.

  2004cited by this paper
• Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas

  2004cited by this paper
• Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

  2004cited by this paper
• Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas

  2003cited by this paper
• DNA repair gene O6‐methylguanine‐DNA methyltransferase: Promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors

  2003cited by this paper
• The Molecular and Genetic Basis of Neurological Tumours

  2002cited by this paper
• The WHO Classification of Tumors of the Nervous System

  2002cited by this paper
• Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.

  2001cited by this paper
• Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.

  2001cited by this paper
• p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas

  2001cited by this paper
• Mutation analysis of p53 in ovarian tumors by DHPLC.

  2001cited by this paper
• Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker.

  2000cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas

  2000cited by this paper
• O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.

  2000cited by this paper
• Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.

  1999cited by this paper
• MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edema

  1997cited by this paper
• Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas

  1997cited by this paper
• A Polymerase Chain Reaction‐based Assay for the Rapid Detection of Gene Amplification in Human Tumors

  1996cited by this paper
• Human brain tumor O6‐methylguanine‐DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy

  1996cited by this paper
• Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.

  1995influential reference
• Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells.

  1994cited by this paper
• Influence of O6‐methylguanine‐DNA methyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumors

  1993cited by this paper
• Response criteria for phase II studies of supratentorial malignant glioma.

  1990cited by this paper

• Deep learning classification of MGMT status of glioblastomas using multiparametric MRI with a novel domain knowledge augmented mask fusion approach

  2025cites this paper
• NovumRNA: Accurate prediction of non-canonical tumor antigens from RNA sequencing data

  2025cites this paper
• Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy

  2025cites this paper
• Decoding MGMT Methylation: A Step Towards Precision Medicine in Glioblastoma

  2025influential citation
• Multi-View MRI Approach for Classification of MGMT Methylation in Glioblastoma Patients

  2025cites this paper
• A multitask framework based on CA-EfficientNetV2 for the prediction of glioma molecular biomarkers

  2025cites this paper
• Deciphering glioblastoma: Unveiling imaging markers for predicting MGMT promoter methylation status.

  2024cites this paper
• Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis

  2024cites this paper
• Quality assessment of the MRI-radiomics studies for MGMT promoter methylation prediction in glioma: a systematic review and meta-analysis

  2024cites this paper
• Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image

  2024cites this paper
• Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas

  2024cites this paper
• Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage

  2024cites this paper
• Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps

  2024cites this paper
• Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis

  2024cites this paper
• Association of IDH1 Mutation and MGMT Promoter Methylation with Clinicopathological Parameters in an Ethnically Diverse Population of Adults with Gliomas in England

  2024cites this paper
• MRI-Based Deep Learning Tools for MGMT Promoter Methylation Detection: A Thorough Evaluation

  2023cites this paper
• Prognostic Significance and Clinicopathological Correlations of Epigenetic MGMT Gene Silencing in High Grade Diffuse Gliomas

  2023cites this paper
• Development of A Radiomic Model for MGMT Promoter Methylation Detection in Glioblastoma Using Conventional MRI

  2023cites this paper
• Discovering Genetic Subtype of Glioblastoma from MRI Scans using Sparse Autoencoders

  2023cites this paper
• Potential of pre-operative MRI features in glioblastoma to predict for molecular stem cell subtype and patient overall survival.

  2023cites this paper
• Malignant Glioma.

  2023cites this paper
• Validation of MRI-Based Models to Predict MGMT Promoter Methylation in Gliomas: BraTS 2021 Radiogenomics Challenge

  2022cites this paper
• Towards an Established Intraoperative Oncological Favorable Tool: Results of Fluorescein-Guided Resection from a Monocentric, Prospective Series of 93 Primary Glioblastoma Patients

  2022cites this paper
• Relationship between molecular characteristics of glioblastoma multiforme and the subventricular zone

  2022cites this paper
• MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study

  2022cites this paper
• Multiparametric MR radiomics in brain glioma: models comparation to predict biomarker status

  2022cites this paper
• Comparison of Glioblastoma Outcomes in Two Geographically and Ethnically Distinct Patient Populations in Disparate Health Care Systems

  2022cites this paper
• Adjusting the Clock: the Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy

  2021cites this paper
• Advanced Imaging and Computational Techniques for the Diagnostic and Prognostic Assessment of Malignant Gliomas

  2021cites this paper
• An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas

  2021cites this paper
• Noninvasive Assessment of O(6)‐Methylguanine‐DNA Methyltransferase Promoter Methylation Status in World Health Organization Grade II–IV Glioma Using Histogram Analysis of Inflow‐Based Vascular‐Space‐Occupancy Combined with Structural Magnetic Resonance Imaging

  2021cites this paper
• Canine presumed glial brain tumors treated with radiotherapy: is there an inferior outcome in tumors contacting the subventricular zone?

  2021cites this paper
• Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy

  2021cites this paper
• Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines

  2021cites this paper
• MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas.

  2020cites this paper
• Die Rolle von Arlts1 im Glioblastoma multiforme

  2020cites this paper
• Brain location and tumor biological markers in high and low grade gliomas: our experience.

  2020cites this paper
• High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient

  2020cites this paper
• Updates on Deep Learning and Glioma: Use of Convolutional Neural Networks to Image Glioma Heterogeneity.

  2020cites this paper
• Imaging of Central Nervous System Tumors Based on the 2016 World Health Organization Classification.

  2020cites this paper
• Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation

  2020cites this paper
• Expression and prognostic value of mRNAs in lower grade glioma with MGMT promoter methylated.

  2020cites this paper
• MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.

  2019cites this paper
• Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.

  2019cites this paper
• Non-Invasive MGMT Status Prediction in GBM Cancer Using Magnetic Resonance Images (MRI) Radiomics Features: Univariate and Multivariate Machine Learning Radiogenomics Analysis

  2019cites this paper
• Radiomics and Machine Learning

  2019cites this paper
• ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy

  2019cites this paper
• Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools

  2019cites this paper
• Imaging scoring systems for preoperative molecular diagnoses of lower-grade gliomas

  2019cites this paper
• Diagnosis and management of multiple high-grade gliomas: a retrospective study

  2019cites this paper
• Predictive markers for MGMT promoter methylation in glioblastomas

  2019cites this paper
• Deep learning can see the unseeable: predicting molecular markers from MRI of brain gliomas.

  2019cites this paper
• Updates in the Neuoroimaging and WHO Classification of Primary CNS Gliomas: A Review of Current Terminology, Diagnosis, and Clinical Relevance From a Radiologic Prospective

  2019cites this paper
• Histogram analysis of 11C-methionine integrated PET/MRI may facilitate to determine the O6-methylguanylmethyltransferase methylation status in gliomas.

  2019cites this paper
• Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy

  2019cites this paper
• Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics

  2018cites this paper
• Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions.

  2018cites this paper
• Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis

  2018cites this paper
• The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis

  2018cites this paper
• Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma

  2018cites this paper
• MRI to MGMT: Predicting methylation status in glioblastoma patients using convolutional recurrent neural networks

  2018cites this paper
• Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas

  2018cites this paper
• Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)

  2018cites this paper
• Bioinformatic analysis of gene expression and methylation regulation in glioblastoma

  2018cites this paper
• Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature?

  2018cites this paper
• Clinically Relevant Imaging Features for MGMT Promoter Methylation in Multiple Glioblastoma Studies: A Systematic Review and Meta-Analysis

  2018influential citation
• A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication

  2018cites this paper
• Chemical exchange saturation transfer (CEST) signal intensity at 7T MRI of WHO IV° gliomas is dependent on the anatomic location

  2018cites this paper
• Molecular Biology and Cellular Signaling Pathways in Glioblastoma

  2018cites this paper
• Correlation of conventional magnetic resonance imaging features with O6-methylguanine-DNA-methyltransferase gene promoter methylation status and survival outcomes in patients with newly diagnosed glioblastoma: Single-center correlative imaging substudy from a prospective clinical trial

  2018cites this paper
• The prognostic value of MGMT promoter methylation in glioblastoma: A meta‐analysis of clinical trials

  2018cites this paper
• Imaging Correlates of Adult Glioma Genotypes.

  2017cites this paper
• Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis

  2017influential citation
• Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO)

  2017cites this paper
• Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma

  2017cites this paper
• Molecular biology of glioblastoma: Classification and mutational locations.

  2017cites this paper
• Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges

  2017cites this paper
• Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma

  2017cites this paper
• Spatial habitats from multiparametric MR imaging are associated with signaling pathway activities and survival in glioblastoma

  2017cites this paper
• CHARLES UNIVERSITY FACULTY OF MEDICINE IN PILSEN

  2016cites this paper
• Assessing the Effects of Software Platforms on Volumetric Segmentation of Glioblastoma

  2016cites this paper
• Radiomics in Brain Tumors: An Emerging Technique for Characterization of Tumor Environment.

  2016cites this paper
• Clinical, Pathological, and Molecular Prognostic Parameters in Glioblastoma Patients Undergoing Chemo- and Radiotherapy

  2016cites this paper
• Chapter 24 – Lessons Learned: Clinical Trials and Other Interventions for Glioblastoma

  2016cites this paper
• An update on the epigenetics of glioblastomas.

  2016cites this paper
• Neuroimaging.

  2016cites this paper
• MRI Texture Analysis Predicts p53 Status in Head and Neck Squamous Cell Carcinoma

  2015influential citation
• Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review

  2015cites this paper
• Pathological spectrum in recurrences of glioblastoma multiforme.

  2015cites this paper
• Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment

  2015cites this paper
• Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis.

  2015cites this paper
• MGMT testing allows for personalised therapy in the temozolomide era

  2015cites this paper
• Predictive biomarkers in diffuse gliomas and non-small cell lung cancer

  2015cites this paper
• Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology.

  2015cites this paper
• 18F-Fluorodeoxyglucose and 11C-methionine positron emission tomography in relation to methyl-guanine methyltransferase promoter methylation in high-grade gliomas

  2015cites this paper
• Imaging Genomics of Glioblastoma: Biology, Biomarkers, and Breakthroughs

  2015cites this paper
• Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

  2015cites this paper
• Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones.

  2015cites this paper
• A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools.

  2015cites this paper
• Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival

  2015cites this paper